FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2018426258> ?p ?o ?g. }

• W2018426258 endingPage "346" @default.
• W2018426258 startingPage "341" @default.
• W2018426258 abstract "Combinations of capecitabine and a taxane are highly active in metastatic breast cancer, and synergy between capecitabine and docetaxel has also been demonstrated. Such combinations potentially would provide a promising non-anthracycline-based alternative for patients with early breast cancer. Non-anthracycline preoperative regimens are a particularly interesting proposition in human epidermal growth factor receptor 2 (HER2)-positive breast cancer, as they offer less cardiotoxicity and thus can be used concomitantly with preoperative trastuzumab therapy. Capecitabine plus docetaxel (XT) and trastuzumab with XT (HXT) are promising non-anthracycline regimens for the preoperative treatment of women with HER2-negative and HER2-positive breast cancer, respectively. The Xeloda in Neoadjuvant (XeNA) trial, an open-label, multicenter, phase II study, independently assesses the efficacy of preoperative XT in HER2-negative and HXT in HER2-positive breast cancer. A particularly important feature of the XeNA study is the use of pathologic complete response (pCR) plus near pCR (npCR) as the primary endpoint. pCR is associated with long-term survival, and although it is valuable as a surrogate marker, pCR has some limitations. Measurement of residual breast cancer burden (RCB) has been proposed as a more practical alternative to predict survival after preoperative chemotherapy. The combination of RCB-0 and RCB-I (npCR) expands the subset of patients shown to benefit from preoperative chemotherapy, and achievement of pCR or npCR is associated with long disease-free survival. In XeNA, the sum of pCR and npCR will facilitate correlative studies designed to identify patients most likely to benefit from XT and HXT and may expedite the clinical evaluation of these novel preoperative regimens." @default.
• W2018426258 created "2016-06-24" @default.
• W2018426258 creator A5002818963 @default.
• W2018426258 creator A5027712976 @default.
• W2018426258 creator A5063914778 @default.
• W2018426258 date "2008-01-01" @default.
• W2018426258 modified "2023-10-17" @default.
• W2018426258 title "XeNA: Capecitabine Plus Docetaxel, With or Without Trastuzumab, as Preoperative Therapy for Early Breast Cancer" @default.
• W2018426258 cites W1949597673 @default.
• W2018426258 cites W1963704957 @default.
• W2018426258 cites W1972861806 @default.
• W2018426258 cites W1984705515 @default.
• W2018426258 cites W1992234802 @default.
• W2018426258 cites W2000696414 @default.
• W2018426258 cites W2017098623 @default.
• W2018426258 cites W2028647675 @default.
• W2018426258 cites W2029409133 @default.
• W2018426258 cites W2032775660 @default.
• W2018426258 cites W2044970916 @default.
• W2018426258 cites W2050761481 @default.
• W2018426258 cites W2052953339 @default.
• W2018426258 cites W2055679225 @default.
• W2018426258 cites W2059955238 @default.
• W2018426258 cites W2075076931 @default.
• W2018426258 cites W2096145980 @default.
• W2018426258 cites W2096149428 @default.
• W2018426258 cites W2104337757 @default.
• W2018426258 cites W2113242459 @default.
• W2018426258 cites W2113670583 @default.
• W2018426258 cites W2131770017 @default.
• W2018426258 cites W2133764807 @default.
• W2018426258 cites W2136270722 @default.
• W2018426258 cites W2137909720 @default.
• W2018426258 cites W2138577761 @default.
• W2018426258 cites W2139510434 @default.
• W2018426258 cites W2141949781 @default.
• W2018426258 cites W2151552922 @default.
• W2018426258 cites W2151809511 @default.
• W2018426258 cites W2153158488 @default.
• W2018426258 cites W2160160977 @default.
• W2018426258 cites W2161791469 @default.
• W2018426258 cites W2164429641 @default.
• W2018426258 cites W2167766783 @default.
• W2018426258 cites W2171958606 @default.
• W2018426258 cites W2523286593 @default.
• W2018426258 cites W30464105 @default.
• W2018426258 cites W2740493297 @default.
• W2018426258 doi "https://doi.org/10.7150/ijms.5.341" @default.
• W2018426258 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2581822" @default.
• W2018426258 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19002271" @default.
• W2018426258 hasPublicationYear "2008" @default.
• W2018426258 type Work @default.
• W2018426258 sameAs 2018426258 @default.
• W2018426258 citedByCount "15" @default.
• W2018426258 countsByYear W20184262582012 @default.
• W2018426258 countsByYear W20184262582013 @default.
• W2018426258 countsByYear W20184262582014 @default.
• W2018426258 countsByYear W20184262582016 @default.
• W2018426258 countsByYear W20184262582018 @default.
• W2018426258 countsByYear W20184262582021 @default.
• W2018426258 crossrefType "journal-article" @default.
• W2018426258 hasAuthorship W2018426258A5002818963 @default.
• W2018426258 hasAuthorship W2018426258A5027712976 @default.
• W2018426258 hasAuthorship W2018426258A5063914778 @default.
• W2018426258 hasBestOaLocation W20184262581 @default.
• W2018426258 hasConcept C121608353 @default.
• W2018426258 hasConcept C126322002 @default.
• W2018426258 hasConcept C143998085 @default.
• W2018426258 hasConcept C203092338 @default.
• W2018426258 hasConcept C2775930923 @default.
• W2018426258 hasConcept C2776694085 @default.
• W2018426258 hasConcept C2776802502 @default.
• W2018426258 hasConcept C2777511904 @default.
• W2018426258 hasConcept C2777909004 @default.
• W2018426258 hasConcept C2778292576 @default.
• W2018426258 hasConcept C2779786085 @default.
• W2018426258 hasConcept C2781190966 @default.
• W2018426258 hasConcept C526805850 @default.
• W2018426258 hasConcept C530470458 @default.
• W2018426258 hasConcept C535046627 @default.
• W2018426258 hasConcept C71924100 @default.
• W2018426258 hasConceptScore W2018426258C121608353 @default.
• W2018426258 hasConceptScore W2018426258C126322002 @default.
• W2018426258 hasConceptScore W2018426258C143998085 @default.
• W2018426258 hasConceptScore W2018426258C203092338 @default.
• W2018426258 hasConceptScore W2018426258C2775930923 @default.
• W2018426258 hasConceptScore W2018426258C2776694085 @default.
• W2018426258 hasConceptScore W2018426258C2776802502 @default.
• W2018426258 hasConceptScore W2018426258C2777511904 @default.
• W2018426258 hasConceptScore W2018426258C2777909004 @default.
• W2018426258 hasConceptScore W2018426258C2778292576 @default.
• W2018426258 hasConceptScore W2018426258C2779786085 @default.
• W2018426258 hasConceptScore W2018426258C2781190966 @default.
• W2018426258 hasConceptScore W2018426258C526805850 @default.
• W2018426258 hasConceptScore W2018426258C530470458 @default.
• W2018426258 hasConceptScore W2018426258C535046627 @default.
• W2018426258 hasConceptScore W2018426258C71924100 @default.
• W2018426258 hasLocation W20184262581 @default.

• next